ABL1 is targeted by Imatinib Mesylate inhibitor which, in a phase I clinical trial for endometrial cancer, while PDGFRA is targeted by Nintedanib, and Dovitinib inhibitors which are currently under phase II clinical trial and Vatalanib as well as Cediranib, inhibitors under phase I clinical trial. The gene discussed is PDGFRA; the disease is endometrial cancer.